Log in

OTCMKTS:RCDTFRecordati News Headlines

$53.27
-2.53 (-4.53 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$53.27
Now: $53.27▼
$53.27
50-Day Range
$47.56
MA: $50.91▼
$55.80
52-Week Range
$36.50
Now: $53.27▼
$55.80
Volume13,155 shs
Average Volume1,584 shs
Market Capitalization$11.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.45

Headlines

Recordati (OTCMKTS RCDTF) News Headlines

Source:
DateHeadline
FY2022 EPS Estimates for Recordati SpA (OTCMKTS:RCDTF) Boosted by Jefferies Financial GroupFY2022 EPS Estimates for Recordati SpA (OTCMKTS:RCDTF) Boosted by Jefferies Financial Group
americanbankingnews.com - August 6 at 8:18 AM
Recordati (OTCMKTS:RCDTF) Rating Lowered to Hold at Jefferies Financial GroupRecordati (OTCMKTS:RCDTF) Rating Lowered to Hold at Jefferies Financial Group
americanbankingnews.com - August 4 at 10:36 AM
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q2 2020 Results - Earnings Call TranscriptRecordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 1 at 6:59 PM
Recordati Industria Chimica e Farmaceutica S.p.A. 2020 Q2 - Results - Earnings Call PresentationRecordati Industria Chimica e Farmaceutica S.p.A. 2020 Q2 - Results - Earnings Call Presentation
seekingalpha.com - July 30 at 3:33 PM
Recordati: Results From the Phase III LINC-3 Study Of ISTURISA® (osilodrostat) for the Treatment of Cushing’s Disease Published in Lancet Diabetes & Endocrinology.Recordati: Results From the Phase III LINC-3 Study Of ISTURISA® (osilodrostat) for the Treatment of Cushing’s Disease Published in Lancet Diabetes & Endocrinology.
www.businesswire.com - July 28 at 8:44 AM
Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing’s Disease Published in Lancet Diabetes & EndocrinologyRecordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing’s Disease Published in Lancet Diabetes & Endocrinology
finance.yahoo.com - July 28 at 8:44 AM
Recordati (OTCMKTS:RCDTF) Sets New 12-Month High at $55.80Recordati (OTCMKTS:RCDTF) Sets New 12-Month High at $55.80
www.americanbankingnews.com - July 22 at 7:06 PM
Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in GermanyIsturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany
finance.yahoo.com - July 16 at 12:31 PM
Recordati: ISTURISA® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing’s DiseaseRecordati: ISTURISA® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing’s Disease
www.businesswire.com - June 17 at 12:41 PM
Recordati Rare Diseases Inc. Announces Availability of ISTURISA® (osilodrostat) in the United StatesRecordati Rare Diseases Inc. Announces Availability of ISTURISA® (osilodrostat) in the United States
www.businesswire.com - May 27 at 12:33 PM
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q1 2020 Results - Earnings Call TranscriptRecordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Andrea Recordati on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 2:29 AM
Recordati declares EUR 0.52 dividendRecordati declares EUR 0.52 dividend
seekingalpha.com - April 29 at 7:47 AM
RECORDATI: Recordati Rare Diseases now holds Isturisa European MARECORDATI: Recordati Rare Diseases now holds Isturisa European MA
www.finanznachrichten.de - April 8 at 7:59 AM
Recordati Industria Chimica e Farmaceutica S.p.A. 2019 Q4 - Results - Earnings Call PresentationRecordati Industria Chimica e Farmaceutica S.p.A. 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 14 at 6:14 PM
This page was last updated on 8/7/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.